Concord Medical Schedules 2022 Annual Meeting of Shareholders
Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2022 annual general meeting of shareholders (the "Meeting") on December 30, 2022, at 10:00 a.m. (Beijing Time)
BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it will hold its 2022 annual general meeting of shareholders (the "Meeting") on December 30, 2022, at 10:00 a.m. (Beijing Time). The meeting will be held at 27/F, Tower A, Global Trade Center, 36 North 3rd Ring Road East, Dongcheng District, Beijing, China. The shareholder record date is November 30, 2022. A copy of the notice of Meeting is available on the Company's investor relations website at https://ir.ccm.cn.
No proposal will be submitted for shareholder approval at the Meeting. Instead, the Meeting will be convened for shareholders who are entitled to vote to discuss Company affairs with management. Concord Medical's annual report on Form 20-F filed with the U.S. Securities and Exchange Commission, containing the Company's audited financial statements for the financial year ended December 31, 2021, is available in the Investor Relations section of the Company's website at http://ir.ccm.cn. The Form 20-F is also available on the SEC's website at http://www.sec.gov.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.
